Drug Evaluation, Preclinical

"Drug Evaluation, Preclinical" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications.

Descriptor ID	D004353
MeSH Number(s)	E05.295.750 E05.337.550
Concept/Terms	Drug Evaluation, Preclinical Drug Evaluation, Preclinical Drug Evaluations, Preclinical Drug Screening Drug Screenings Screening, Drug Screenings, Drug Evaluation Studies, Drug, Pre-Clinical Preclinical Drug Evaluations Evaluation, Preclinical Drug Evaluations, Preclinical Drug Preclinical Drug Evaluation Drug Evaluation Studies, Preclinical Evaluation Studies, Drug, Preclinical Medicinal Plants Testing, Preclinical Medicinal Plants Testing, Preclinical

Below are MeSH descriptors whose meaning is more general than "Drug Evaluation, Preclinical".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Investigative Techniques [E05]
Drug Discovery [E05.295]
Drug Evaluation, Preclinical [E05.295.750]
Evaluation Studies as Topic [E05.337]
Drug Evaluation, Preclinical [E05.337.550]

Below are MeSH descriptors whose meaning is related to "Drug Evaluation, Preclinical".

Below are MeSH descriptors whose meaning is more specific than "Drug Evaluation, Preclinical".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Drug Evaluation, Preclinical" by people in this website by year, and whether "Drug Evaluation, Preclinical" was a major or minor topic of these publications.

Bar chart showing 81 publications over 23 distinct years, with a maximum of 8 publications in 2015

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	0	2	2
1997	0	2	2
1998	0	1	1
2000	0	1	1
2002	0	3	3
2003	0	1	1
2004	1	3	4
2005	0	2	2
2006	1	2	3
2007	2	1	3
2008	1	4	5
2009	0	4	4
2010	0	1	1
2011	0	5	5
2012	0	4	4
2013	0	6	6
2014	0	5	5
2015	1	7	8
2016	4	3	7
2017	0	5	5
2018	0	4	4
2019	0	3	3
2020	0	2	2

Below are the most recent publications written about "Drug Evaluation, Preclinical" by people in Profiles.

Lorthiois E, Roache J, Barnes-Seeman D, Altmann E, Hassiepen U, Turner G, Duvadie R, Hornak V, Karki RG, Schiering N, Weihofen WA, Perruccio F, Calhoun A, Fazal T, Dedic D, Durand C, Dussauge S, Fettis K, Tritsch F, Dentel C, Druet A, Liu D, Kirman L, Lachal J, Namoto K, Bevan D, Mo R, Monnet G, Muller L, Zessis R, Huang X, Lindsley L, Currie T, Chiu YH, Fridrich C, Delgado P, Wang S, Hollis-Symynkywicz M, Berghausen J, Williams E, Liu H, Liang G, Kim H, Hoffmann P, Hein A, Ramage P, D'Arcy A, Harlfinger S, Renatus M, Ruedisser S, Feldman D, Elliott J, Sedrani R, Maibaum J, Adams CM. Structure-Based Design and Preclinical Characterization of Selective and Orally Bioavailable Factor XIa Inhibitors: Demonstrating the Power of an Integrated S1 Protease Family Approach. J Med Chem. 2020 08 13; 63(15):8088-8113.

View in: PubMed
O'Neill MJ, Chan K, Jaynes JM, Knotts Z, Xu X, Abisoye-Ogunniyan A, Guerin T, Schlomer J, Li D, Cary JW, Rajasekaran K, Yates C, Kozlov S, Andresson T, Rudloff U. LC-MS/MS assay coupled with carboxylic acid magnetic bead affinity capture to quantitatively measure cationic host defense peptides (HDPs) in complex matrices with application to preclinical pharmacokinetic studies. J Pharm Biomed Anal. 2020 Mar 20; 181:113093.

View in: PubMed
Wadsworth PA, Folorunso O, Nguyen N, Singh AK, D'Amico D, Powell RT, Brunell D, Allen J, Stephan C, Laezza F. High-throughput screening against protein:protein interaction interfaces reveals anti-cancer therapeutics as potent modulators of the voltage-gated Na+ channel complex. Sci Rep. 2019 11 15; 9(1):16890.

View in: PubMed
Villalta F, Rachakonda G. Advances in preclinical approaches to Chagas disease drug discovery. Expert Opin Drug Discov. 2019 11; 14(11):1161-1174.

View in: PubMed
Toropova AP, Toropov AA, Benfenati E, Leszczynska D, Leszczynski J. Virtual Screening of Anti-Cancer Compounds: Application of Monte Carlo Technique. Anticancer Agents Med Chem. 2019; 19(2):148-153.

View in: PubMed
Gonzalez-Cadavid NF, Rajfer J. The two phases of the clinical validation of preclinical translational mechanistic research on PDE5 inhibitors since Viagra's advent. A personal perspective. Int J Impot Res. 2019 Mar; 31(2):57-60.

View in: PubMed
D'Antoni ML, Mitchell BI, McCurdy S, Byron MM, Ogata-Arakaki D, Chow D, Mehta NN, Boisvert WA, Lefebvre E, Shikuma CM, Ndhlovu LC, Baumer Y. Cenicriviroc inhibits trans-endothelial passage of monocytes and is associated with impaired E-selectin expression. J Leukoc Biol. 2018 12; 104(6):1241-1252.

View in: PubMed
Rodriguez F, Iniguez E, Pena Contreras G, Ahmed H, Costa TEMM, Skouta R, Maldonado RA. Development of Thiophene Compounds as Potent Chemotherapies for the Treatment of Cutaneous Leishmaniasis Caused by Leishmania major. Molecules. 2018 07 04; 23(7).

View in: PubMed
Campos-Gomez J, Benitez JA. A simple cell-based high throughput screening (HTS) assay for inhibitors of Salmonella enterica RNA polymerase containing the general stress response regulator RpoS (sS). J Microbiol Methods. 2018 07; 150:1-4.

View in: PubMed
Hu L, Ge A, Wang X, Wang S, Yue X, Wang J, Feng X, Du W, Liu BF. Real-time monitoring of immune responses under pathogen invasion and drug interference by integrated microfluidic device coupled with worm-based biosensor. Biosens Bioelectron. 2018 Jul 01; 110:233-238.

View in: PubMed

People

Explore

Similar Concepts

Top Journals